Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy

被引：0
|
作者：
Zisman, Liron Pola
Gushterova, Irena
LaSalle, Thomas
Blaum, Emily
Sharova, Tatyana
Liu, Mofei
Giobbie-Hurder, Anita
Sade-Feldman, Moshe
Yizhak, Keren
Hacohen, Nir
Sullivan, Ryan J.
机构：
[1] Rambam Hlth Care, Div Oncol, Haifa, Israel
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Massachusetts Gen Hosp, Surg Oncol, Canc Ctr, Boston, MA USA
[4] Harvard Med Sch, Dana Farber Canc Inst, Div Biostat, Dept Data Sci, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Massachusetts Inst Technol MIT & Harvard, Broad Inst, Cambridge, MA USA
[7] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
[8] Harvard Med Sch HMS, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[9] Massachusetts Gen Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21503
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.
    Zisman, Liron
    Lawrence, Donald P.
    McDermott, David F.
    Liu, Mofei
    Buchbinder, Elizabeth Iannotti
    Gushterova, Irena
    Goyne, Anna L. K.
    Cohen, Justine Vanessa
    Miller, David Michael
    LaSalle, Thomas
    Blaum, Emily
    Frederick, Dennie T.
    Sharova, Tatyana
    Boland, Genevieve Marie
    Giobbie-Hurder, Anita
    Sade-Feldman, Moshe
    Yizhak, Keren
    Hacohen, Nir
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
    Cooper, Zachary A.
    Reuben, Alexandre
    Amaria, Rodabe N.
    Wargo, Jennifer A.
    ONCOIMMUNOLOGY, 2014, 3 (09)
  • [3] Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
    Buchbinder, Elizabeth I.
    Weirather, Jason L.
    Manos, Michael
    Quattrochi, Brian J.
    Sholl, Lynette M.
    Brennick, Ryan C.
    Bowling, Peter
    Bailey, Nancy
    Magarace, Lisa
    Ott, Patrick A.
    Haq, Rizwan
    Izar, Benjamin
    Giobbie-Hurder, Anita
    Hodi, F. Stephen
    CANCER MEDICINE, 2021, 10 (08): : 2627 - 2635
  • [4] Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy
    Lv, Xiaohui
    Ding, Min
    Liu, Yan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade
    Byrne, Elizabeth H.
    Fisher, David E.
    CANCER, 2017, 123 : 2143 - 2153
  • [6] A Novel Murine Tumor System for Optimizing Combined RAS-Targeted Therapy and Immune Checkpoint Blockade in NSCLC
    Arisato, Hitoki
    Noguchi, Takuro
    Shiiya, Akihiko
    Kinoshita, Ichiro
    Akita, Hirotoshi
    Konno, Satoshi
    CANCER SCIENCE, 2024, 115 : 182 - 182
  • [7] Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy.
    Colen, Rivka R.
    Ologun, Gabriel O.
    Zinn, Pascal
    Murat, A. K.
    Arora, Reetakshi
    Burton, Elizabeth M.
    Glitza, Isabella Claudia
    Tawbi, Hussein Abdul-Hassan
    Patel, Sapna Pradyuman
    Diab, Adi
    Wong, Michael K.
    McQuade, Jennifer Leigh
    Ross, Merrick I.
    Ahmed, Sara
    Elshafeey, Nabil
    Gershenwald, Jeffrey E.
    Davies, Michael A.
    Tetzlaff, Michael T.
    Amaria, Rodabe Navroze
    Wargo, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] T cell immune landscape in melanoma patients before and post immune checkpoint blockade treatment
    Luo, Ying
    Yao, Chen
    Wu, Tuoqi
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [9] T cell immune landscape in melanoma patients before and post immune checkpoint blockade treatment
    Luo, Ying
    Yao, Chen
    Wu, Tuoqi
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [10] Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Patrick Schummer
    Bastian Schilling
    Anja Gesierich
    American Journal of Clinical Dermatology, 2020, 21 : 493 - 504
12345